MoonLake Immunotherapeutics (MLTX) Research & Development (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Research & Development of $54.5 million for Q1 2026, up 49.52% year-over-year from $36.5 million in Q1 2025, and down 2.66% quarter-over-quarter from $56.0 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Research & Development (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Research & Development history runs 6 years deep, the most recent figure standing at $54.5 million for Q1 2026.
- In Q1 2026, Research & Development rose 49.52% year-over-year to $54.5 million; the TTM figure through Mar 2026 stood at $220.9 million (up 62.18% YoY), while the FY2025 annual figure was $202.9 million, up 79.89% from the prior year.
- Research & Development for Q1 2026 stood at $54.5 million, down from $56.0 million in the prior quarter.
- The five-year high for Research & Development was $60.6 million in Q3 2025, with the low at $7.4 million in Q1 2023.
- The 5-year median for Research & Development is $13.0 million (2024), against an average of $26.1 million.
- Peak annual rise in Research & Development reached 1247.88% in 2022, while the deepest fall reached 68.0% in 2022.
- MoonLake Immunotherapeutics' Research & Development stood at $11.4 million in 2022, then slipped by 28.77% to $8.1 million in 2023, then soared by 398.39% to $40.4 million in 2024, then surged by 38.77% to $56.0 million in 2025, then retreated by 2.66% to $54.5 million in 2026.
- Business Quant data shows MLTX's Research & Development at $54.5 million in Q1 2026, $56.0 million in Q4 2025, and $60.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 50.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.22 Mn |
| Mar 31, 2026 | 54.52 Mn |
| Dec 31, 2025 | 56.01 Mn |
| Sep 30, 2025 | 60.64 Mn |
| Jun 30, 2025 | 49.76 Mn |
| Mar 31, 2025 | 36.46 Mn |
| Dec 31, 2024 | 40.36 Mn |
| Sep 30, 2024 | 35.74 Mn |
| Jun 30, 2024 | 23.66 Mn |
| Mar 31, 2024 | 13.01 Mn |
| Dec 31, 2023 | 8.10 Mn |
| Sep 30, 2023 | 7.59 Mn |
| Jun 30, 2023 | 8.70 Mn |
| Mar 31, 2023 | 7.42 Mn |
| Dec 31, 2022 | 11.37 Mn |
| Sep 30, 2022 | 9.02 Mn |
| Jun 30, 2022 | 11.40 Mn |
| Mar 31, 2022 | 10.45 Mn |
| Dec 31, 2021 | 35.53 Mn |
| Sep 30, 2021 | 669,528.00 |